ABBV
AbbVie Inc.NYSEValuation snapshot
Above base casePrice is between the base and bull cases.
Price as of Aug 17, 2026 · Valuation Aug 16, 2026
What drives ABBV's base case?
base-case thesisAbbVie has already navigated its biggest risk: Humira sales have collapsed by more than a third a year, yet total revenue still grew 10.2% last quarter because Skyrizi and Rinvoq together brought in over $8 billion in three months. Management has publicly committed to high-single-digit annual sales growth through 2029 and raised its 2026 outlook twice, so this case follows that path and then lets growth ease to around 3% as the guidance window closes. Reported profitability has been artificially depressed by write-offs on acquired drug programs — swinging from 12% to 38% of sales across recent quarters — and this case assumes it settles at a healthier middle level as those charges fade and older Allergan-era costs roll off. Taxes drift up slightly from the company's unusually low current rate as global minimum-tax rules take hold, and the company keeps buying pipeline assets like Apogee at a steady, financeable pace.
What shapes the assumptions
Skyrizi and Rinvoq scaling toward the company's 2027 target
Combined Q2 2026 revenue of $8.03B, growing ~24% operationally
Raises revenue growth
Neuroscience portfolio compounding
Q2 2026 neuroscience revenue $3.228B, +20.3% year over year
Raises revenue growth
Acquisition write-offs normalizing
Reported operating margin recovering from 12.1% (Q3 2025) to 37.9% (Q2 2026)
Raises operating margin
Low-taxed international IP structure
Q2 2026 GAAP tax rate of 15.5% vs ~14.5% full-year guidance
Lowers tax rate
Steady debt-funded pipeline acquisition cadence
$9.93B senior notes priced August 2026 to fund Apogee
Raises reinvestment
Each driver links a business metric to the forecast assumption it shapes — the basis for this case, not investment advice.
Why the gap?
The market is pricing this as if revenue grows 13.7% a year. Over the last 5 years it grew 3.7% a year — so the price assumes far more than it has delivered.
What else could explain it?›
- Or, holding growth steady
- the price is also consistent with a 46.4% operating margin, against the 32.5% assumed here.
- How confident is this estimate?
- Robustness 53.0/10 (Moderate) — some of any gap is our own uncertainty rather than disagreement.
- What would change the answer?
- Which assumption this valuation swings on, and by how much.
Many combinations of assumptions reproduce the same price. These are ways to read what the market might be expecting, not the market's actual view. How this is worked out
Research & assumptions
Inspect the valuation thesis, cases, risks, evidence, and model inputs.
View details
Research & assumptions
Inspect the valuation thesis, cases, risks, evidence, and model inputs.
Three independently researched cases generated automatically from published financials. Every assumption is justified and cited; the discount rate is computed from researched market inputs.
Base inputs from financials
source period →Base revenue (TTM)
$64.4B
Diluted shares
1,771,000,000
Net cash
—
Bear
low confidence$95.64
IV / share
-61.7% vs $249.46
- Explicit cash flows
- $22.66
- Terminal value
- $72.98
- Net cash
- $0.00
- Intrinsic value / share
- $95.64
76.3% of the value rests on the terminal value — high dependency. A small change to terminal growth moves the valuation a lot — see terminal growth below.
Revenue growth4.0% → 2.5% → 1.5% → -0.5% → 0.0%medium
How derived: Starting from the FY2026 guided base of roughly $67.6B and Q2 2026's +10.2% growth, this case assumes the two growth engines decelerate fast as Skyrizi/Rinvoq mature into a crowded IBD/derm market, while the already-shrinking pieces of the portfolio (Humira -35.9%, oncology -1.5%, aesthetics ~flat at +0.3%) keep dragging, so reported growth fades to low single digits by 2029 and turns slightly negative as Vraylar loses exclusivity and Medicare price negotiation reaches the immunology franchise.
Why this confidence: Company-guided FY2026 revenue base anchors year one ↑, Documented precedent of a real AbbVie patent-cliff decline in 2023 ↑, Five-year horizon extends well past management's stated visibility ↓, Timing and severity of Medicare price negotiation on immunology is unknown ↓, Path contradicts current reported +10.2% quarterly growth ↓
Evidence for
- Global Humira net revenues fell to $756 million in Q2 2026, down 35.9% reported on biosimilar competition, showing how quickly an AbbVie franchise can erode post-exclusivity.[AbbVie Reports Second-Quarter 2026 Financial Results]· primary
- Aesthetics revenue was $1.282 billion, up only 0.3% reported and down 0.9% operationally, and oncology fell 1.5% reported — two portfolios contributing zero or negative growth.[AbbVie Q2 2026 Financial Results]· primary
- The 2023 Humira cliff produced an actual reported revenue decline of -6.4% for the full company, evidence that concentrated franchises can push total growth negative.[AbbVie FY2024 and Q4 2024 Results]· primary
- Johnson & Johnson's Tremfya and other entrants are competing directly in the growing IBD arena where Skyrizi and Rinvoq are gaining share, a direct threat to the growth runway.[AbbVie holds its own in growing IBD arena despite J&J]· secondary
Evidence against
- AbbVie raised its full-year 2026 revenue outlook by $300 million to approximately $67.6 billion, indicating momentum rather than deceleration entering the forecast window.[AbbVie Reports Second-Quarter 2026 Financial Results]· primary
- Management has reaffirmed a high-single-digit compound annual revenue growth rate through 2029 off a 2024 base, well above this case's path.[AbbVie backs high single digit CAGR through 2029]· primary
- Skyrizi grew 24% operationally to $5.5 billion and Rinvoq 23.7% to over $2.5 billion in Q2 2026 — neither shows the deceleration this case assumes.[AbbVie Q2 2026 Financial Results]· primary
Operating margin27.5%medium
How derived: The four most recent reported quarters (12.1%, 27.3%, 26.6%, 37.9%) blend to roughly 26% of the $64.4B trailing revenue base, and this case assumes only modest improvement to 27.5% because continued acquired-IPR&D charges from deals like Apogee, ongoing intangible amortization, and pricing pressure offset the natural mix benefit of Humira shrinking.
Why this confidence: Four quarters of actual reported margin data anchor the starting point ↑, Extreme quarter-to-quarter margin volatility from IPR&D charges ↓, Future acquisition charge timing is inherently unforecastable ↓, Direction of travel (Humira mix-out) is well documented ↑
Evidence for
- Reported quarterly operating margin swung from 12.1% (Q3 2025) to 37.9% (Q2 2026) and was negative (-9.9%) in Q4 2024, demonstrating that charge-driven volatility routinely suppresses AbbVie's reported margin.[AbbVie Q2 2026 10-Q]· primary
- AbbVie is adding the Apogee Therapeutics acquisition, which management said dilutes near-term earnings and brings additional R&D and acquisition-related expense.[ABBV Q2 Earnings Call Balances Growth With Apogee Dilution]· secondary
Evidence against
- Q2 2026 reported operating margin reached 37.9%, materially above this case's 27.5% target, showing the underlying earnings power when charges are light.[AbbVie Q2 2026 10-Q]· primary
- Management raised full-year adjusted EPS guidance to $13.87–$14.07 even while absorbing Apogee dilution, implying profitability is expanding not stalling.[AbbVie Reports Second-Quarter 2026 Financial Results]· primary
Tax rate19.0%medium
How derived: AbbVie's Q2 2026 GAAP rate was 15.5% against a guided full-year non-GAAP rate near 14.5%, and this case steps that up to 19% on the view that the OECD Pillar Two 15% global minimum tax, expiring US foreign-derived income incentives, and a shrinking pool of low-taxed legacy IP income push the effective rate toward the US statutory level over five years.
Why this confidence: Current-period GAAP and guided rates are both disclosed by the company ↑, Five-year tax-policy trajectory is speculative ↓, Company has a long track record of defending a low rate ↓
Evidence for
- AbbVie's Q2 2026 GAAP effective tax rate was 15.5%, already above the 14.5% non-GAAP full-year guide, showing GAAP taxes run higher than the adjusted figure.[AbbVie Q2 2026 10-Q]· primary
- AbbVie discloses that its effective tax rate reflects the jurisdictional mix of earnings and is exposed to changes in tax law, including global minimum tax regimes.[AbbVie Q1 2026 10-Q]· primary
Evidence against
- AbbVie guided to an approximately 14.5% full-year 2026 non-GAAP tax rate, far below this case's 19% assumption, and has sustained low-teens rates for years.[AbbVie Reports Second-Quarter 2026 Financial Results]· primary
Reinvestment rate36.0%low
How derived: AbbVie's own capital expenditure is small relative to a $64.4B revenue base, but its growth is bought — the company just priced $9.93B of senior notes largely to fund Apogee — and in this case, with organic growth fading toward zero, it must spend a high 36% of after-tax operating profit on business development just to hold revenue flat, i.e. poor returns on reinvested capital.
Why this confidence: Reinvestment via M&A is lumpy and not disclosed as a forward plan ↓, Accounting reinvestment is distorted by very large intangible amortization exceeding capex ↓, The scale of recent BD spend is documented in SEC filings ↑
Evidence for
- AbbVie priced approximately $9.93 billion of senior notes on August 5, 2026, with proceeds primarily funding the Apogee Therapeutics acquisition — evidence that growth is capital-intensive and externally sourced.[AbbVie Form 424B5]· primary
- AbbVie has added roughly $8 billion of net new debt for the Apogee deal, raising leverage before any revenue contribution arrives.[AbbVie Piles on $8 Billion in Debt for Its Apogee Deal]· secondary
Evidence against
- Management stated it aims to preserve an A2/A- credit rating and return to roughly 2x net leverage within two to three years of closing, implying deal spending will be throttled rather than escalated.[AbbVie prices $9.9B senior notes to fund acquisition]· secondary
- Recent acquisitions (ImmunoGen, Cerevel) are already generating oncology and neuroscience revenue, suggesting reinvestment has been productive rather than value-destroying.[AbbVie Q2 2026 Financial Results]· primary
Terminal growth1.5%medium
How derived: A mature branded-pharma business cannot outgrow the economy forever, and this case sets perpetual growth at 1.5% — below long-run US nominal GDP — because Medicare price negotiation and the serial patent cliffs AbbVie has already lived through (Humira down to $756 million a quarter) imply structurally negative price and periodic revenue resets after the forecast window.
Why this confidence: Bounded below the risk-free rate, an internally consistent constraint ↑, Perpetual assumptions are unobservable by nature ↓, Grounded in AbbVie's own documented patent-cliff history ↑
Evidence for
- Humira revenue of $756 million fell 35.9% year over year in Q2 2026, illustrating the permanent step-downs that cap a pharma company's perpetual growth.[AbbVie Q2 2026 Results]· primary
- AbbVie's own multi-year record includes a full-year revenue decline of -6.4% in 2023, showing growth is not monotonic across cycles.[AbbVie FY2024 Results]· primary
Evidence against
- The 10-year Treasury yield of about 4.7% implies long-run nominal growth capacity well above 1.5%, so this terminal rate is a deliberately conservative haircut.[Federal Reserve H.15 Selected Interest Rates]· primary
Base
low confidence$174.83
IV / share
-29.9% vs $249.46
- Explicit cash flows
- $34.99
- Terminal value
- $139.83
- Net cash
- $0.00
- Intrinsic value / share
- $174.83
80.0% of the value rests on the terminal value — high dependency. A small change to terminal growth moves the valuation a lot — see terminal growth below.
base revenue growth (avg 5%) runs well above the trailing -12% trend
Revenue growth7.5% → 6.5% → 5.5% → 3.5% → 3.0%high
How derived: Management guides to a high-single-digit revenue CAGR through 2029 from the $56.3B 2024 base, which implies roughly $82–83B by 2029 and about 7% average growth in 2027–2029 off the guided ~$67.6B 2026 level; this case takes that path at 7.5%/6.5%/5.5% and then fades to 3.5%/3.0% as the guidance window closes and Vraylar and other mid-portfolio assets approach exclusivity loss.
Why this confidence: Explicit multi-year revenue CAGR guidance from management through 2029 ↑, Product-level 2027 revenue targets disclosed for Skyrizi and Rinvoq ↑, Guidance raised twice in 2026, showing forecast reliability ↑, Years four and five fall outside any company guidance ↓
Evidence for
- AbbVie reaffirmed expectations for a high-single-digit compound annual revenue growth rate through 2029, using 2024 as the base year.[AbbVie backs high single digit CAGR through 2029]· primary
- AbbVie raised full-year 2026 revenue guidance by $300 million to approximately $67.6 billion after Q2 revenue of $16.99 billion grew 10.2%.[AbbVie Reports Second-Quarter 2026 Financial Results]· primary
- Management raised combined Skyrizi and Rinvoq 2027 revenue guidance to more than $31 billion (Skyrizi >$20B, Rinvoq >$11B), up about $4 billion from prior guidance.[AbbVie FY2024 and Q4 2024 Results]· primary
- Neuroscience revenue grew 20.3% to $3.228 billion in Q2 2026, with Vraylar +18.9% and Qulipta +30.9%, providing a second growth pillar beyond immunology.[AbbVie Q2 2026 Financial Results]· primary
Evidence against
- Humira fell 35.9% to $756 million and oncology declined 1.5% in Q2 2026, meaning parts of the portfolio actively subtract from the growth rate.[AbbVie: Skyrizi And Rinvoq Generate $8.03 Billion As Humira Revenue Falls 36%]· secondary
- Management's own guidance horizon ends in 2029, so the final two years of this five-year path (2030–2031) are unguided extrapolation.[AbbVie Q4 2025 Earnings Call Transcript]· primary
Operating margin32.5%medium
How derived: The last four reported quarters average roughly 26% operating margin on $64.4B of revenue, but the trajectory is clearly upward — Q3 2025's 12.1% reflected heavy one-time charges while Q2 2026 reached 37.9% — so this case settles at 32.5%, assuming Allergan-era intangible amortization steps down and high-margin Skyrizi and Rinvoq keep gaining mix share, partially offset by continuing deal-related charges.
Why this confidence: Eight quarters of actual reported margin data available ↑, Clear directional trend as Humira mix shrinks and charges normalize ↑, High quarter-to-quarter volatility from non-recurring charges ↓, Company does not guide to a GAAP operating margin target ↓
Evidence for
- Reported operating margin improved from -9.9% in Q4 2024 and 12.1% in Q3 2025 to 37.9% in Q2 2026, a clear upward trend as charges normalize.[AbbVie Q2 2026 10-Q]· primary
- AbbVie raised full-year 2026 adjusted EPS guidance to $13.87–$14.07 while absorbing Apogee acquisition dilution, indicating expanding underlying profitability.[AbbVie Reports Second-Quarter 2026 Financial Results]· primary
Evidence against
- Quarterly reported operating margin has ranged from negative to nearly 38% within eight quarters, so any single target masks large swings driven by acquired-IPR&D charges.[AbbVie Q1 2026 10-Q]· primary
- The Apogee acquisition adds near-term dilution and further acquisition-related expense that will hold reported margins below the adjusted figure.[ABBV Q2 Earnings Call Balances Growth With Apogee Dilution]· secondary
Tax rate16.5%high
How derived: AbbVie reported a 15.5% GAAP effective tax rate in Q2 2026 against a ~14.5% guided non-GAAP full-year rate, and this case uses 16.5% to allow for modest upward drift over five years from the OECD 15% global minimum tax and a gradually less favorable jurisdictional earnings mix, while still reflecting AbbVie's structurally low-tax IP footprint.
Why this confidence: Company explicitly guides a full-year tax rate ↑, Current-quarter GAAP rate disclosed in the 10-Q ↑, Tax rates are among the most stable and best-disclosed forecast inputs ↑, Multi-year international tax-law change adds uncertainty ↓
Evidence for
- AbbVie's Q2 2026 GAAP effective tax rate was 15.5% and its adjusted rate 14.7%, with full-year non-GAAP guidance of approximately 14.5%.[AbbVie Reports Second-Quarter 2026 Financial Results]· primary
- AbbVie's 10-Q discloses that its effective rate depends on jurisdictional earnings mix and is subject to enacted and pending global tax legislation.[AbbVie Q2 2026 10-Q]· primary
Evidence against
- AbbVie's guided 14.5% non-GAAP rate is below this 16.5% assumption, so the case may be too conservative if the company continues to defend its current structure.[AbbVie Q2 2026 Results]· primary
Reinvestment rate27.0%low
How derived: AbbVie's physical capital needs are light relative to a $64.4B revenue base, but it reliably converts a meaningful share of after-tax operating profit into acquired pipeline — ImmunoGen, Cerevel and now the debt-funded Apogee deal — so this case assumes about 27% of after-tax operating profit is reinvested, consistent with sustaining mid-single-digit growth alongside management's stated intent to return to roughly 2x net leverage.
Why this confidence: M&A-driven reinvestment is lumpy and not forward-guided ↓, Intangible amortization distorts the accounting reinvestment measure ↓, Recent deal sizes and financing are documented in SEC filings ↑
Evidence for
- AbbVie priced approximately $9.93 billion of senior notes in August 2026 largely to fund the Apogee Therapeutics acquisition, confirming ongoing large-scale reinvestment through M&A.[AbbVie Form 424B5]· primary
- Management stated it targets roughly 2x net leverage within two to three years of the Apogee close, implying disciplined but continuing deal activity.[AbbVie prices $9.9B senior notes to fund acquisition]· secondary
Evidence against
- AbbVie's reported depreciation and amortization far exceeds its capital expenditure because of Allergan intangibles, so accounting-based reinvestment measures can appear negative and understate true growth spending.[AbbVie Q2 2026 10-Q]· primary
- AbbVie pays a large and growing dividend (forward yield near 2.8%), constraining how much operating cash flow is available for reinvestment.[AbbVie Key Statistics]· secondary
Terminal growth2.2%medium
How derived: Perpetual growth must sit below the risk-free rate of about 4.7%, and this case uses 2.2% — roughly long-run inflation — on the reasoning that a diversified branded-pharma portfolio with a renewing pipeline can hold volume gains and inflation-level pricing in perpetuity, but net US price realization is structurally negative under Medicare negotiation, so no real growth premium is warranted.
Why this confidence: Anchored to an observable, cited risk-free rate ceiling ↑, Consistent with a decade of AbbVie's own revenue history ↑, Perpetuity assumptions are unverifiable by construction ↓
Evidence for
- The 10-year Treasury constant maturity yield was about 4.7% in mid-August 2026, setting a hard ceiling well above this 2.2% perpetual rate.[Federal Reserve H.15 Selected Interest Rates]· primary
- AbbVie's revenue has grown from $22.9 billion in 2015 to a guided ~$67.6 billion in 2026, demonstrating a durable long-run compounding franchise rather than a runoff business.[AbbVie Q2 2026 Results]· primary
Evidence against
- AbbVie's 2023 revenue fell 6.4% on the Humira cliff, showing that perpetual smooth growth is a simplification for a patent-driven business.[AbbVie FY2024 Results]· primary
Bull
low confidence$274.29
IV / share
+10.0% vs $249.46
- Explicit cash flows
- $47.65
- Terminal value
- $226.65
- Net cash
- $0.00
- Intrinsic value / share
- $274.29
82.6% of the value rests on the terminal value — high dependency. A small change to terminal growth moves the valuation a lot — see terminal growth below.
bull revenue growth (avg 7%) runs well above the trailing -12% trend
Revenue growth10.0% → 9.0% → 7.5% → 5.5% → 4.5%medium
How derived: AbbVie is currently growing at 10.2% with Skyrizi up 24% and Rinvoq up 23.7% operationally, and management has already raised the combined 2027 target for those two drugs by $4 billion to over $31 billion; this case assumes that momentum persists — new indications, a recovering aesthetics market, and Apogee/Cerevel/ImmunoGen pipeline assets launching — so growth holds double digits into 2027 and only gradually fades to the mid-single digits by 2031.
Why this confidence: Two consecutive quarters of actual double-digit reported growth ↑, Management's history of raising both annual and product-level guidance ↑, Path exceeds management's own stated long-term CAGR ↓, Depends on aesthetics and oncology inflecting, which has not yet happened ↓
Evidence for
- Q2 2026 net revenues of $16.99 billion grew 10.2%, and Q1 2026 grew 12.4% — two consecutive quarters of double-digit growth.[AbbVie Reports Second-Quarter 2026 Financial Results]· primary
- AbbVie raised combined Skyrizi and Rinvoq 2027 guidance by roughly $4 billion to more than $31 billion, a demonstrated pattern of upward revision.[AbbVie FY2024 and Q4 2024 Results]· primary
- Management said Rinvoq is on pace for 30% growth in gastroenterology this year and cited multiple 2026 regulatory approvals plus second-half data readouts.[AbbVie Q2 2026 Earnings Call Transcript]· primary
- AbbVie raised its full-year 2026 revenue outlook to approximately $67.6 billion even while absorbing Apogee acquisition dilution.[AbbVie Q2 2026 Financial Results]· primary
Evidence against
- Management's own long-term commitment is only a high-single-digit CAGR through 2029, below this case's 10% and 9% early-year assumptions.[AbbVie backs high single digit CAGR through 2029]· primary
- Aesthetics grew just 0.3% reported (-0.9% operationally) and oncology fell 1.5% in Q2 2026, so the recovery this case assumes is not yet visible in reported results.[AbbVie Q2 2026 Results]· primary
- Johnson & Johnson and other entrants are competing aggressively in the IBD market that is driving Skyrizi and Rinvoq growth.[AbbVie holds its own in growing IBD arena despite J&J]· secondary
Operating margin37.5%medium
How derived: AbbVie actually delivered a 37.9% reported operating margin in Q2 2026 — a quarter with relatively light acquisition charges — and this case assumes that becomes the sustainable level as the last of the Allergan intangible amortization rolls off, Humira's low-margin decline finishes, and high-margin Skyrizi, Rinvoq and neuroscience products dominate the revenue mix with operating leverage on a fixed sales infrastructure.
Why this confidence: Target equals an actually reported quarterly result, not an extrapolation ↑, Assumes the best recent quarter becomes the sustained run-rate ↓, Recurring acquisition charges are structurally likely to continue ↓, Mix shift toward higher-margin products is well documented ↑
Evidence for
- AbbVie reported a 37.9% operating margin in Q2 2026, proving this level is achievable with the current cost base.[AbbVie Q2 2026 10-Q]· primary
- Full-year 2026 adjusted EPS guidance of $13.87–$14.07 was raised even while absorbing Apogee dilution, indicating strong underlying operating leverage.[AbbVie Reports Second-Quarter 2026 Financial Results]· primary
Evidence against
- The trailing four quarters average only about 26% operating margin, and Q3 2025 was 12.1%, so 37.9% is the best quarter rather than the norm.[AbbVie Q1 2026 10-Q]· primary
- AbbVie's continued acquisition cadence, including Apogee, will keep generating acquired-IPR&D charges that depress reported margins.[ABBV Q2 Earnings Call Balances Growth With Apogee Dilution]· secondary
Tax rate14.5%high
How derived: AbbVie explicitly guides to a roughly 14.5% full-year 2026 non-GAAP tax rate (14.7% adjusted in Q2), and this case assumes the company sustains that rate through the forecast by keeping high-value IP in low-tax jurisdictions and offsetting global minimum-tax exposure with R&D credits and jurisdictional planning.
Why this confidence: Directly equals a company-guided rate for the current year ↑, Corroborated by the reported Q2 2026 adjusted rate of 14.7% ↑, Assumes no upward drift over five years despite global minimum-tax rules ↓
Evidence for
- AbbVie forecasts a full-year 2026 non-GAAP tax rate of approximately 14.5%, with the Q2 2026 adjusted rate at 14.7%.[AbbVie Reports Second-Quarter 2026 Financial Results]· primary
Evidence against
- AbbVie's Q2 2026 GAAP effective tax rate was 15.5%, a full point above the non-GAAP figure this case adopts.[AbbVie Q2 2026 10-Q]· primary
- AbbVie discloses that its effective tax rate is exposed to changes in tax legislation and the jurisdictional mix of earnings, making a flat five-year rate optimistic.[AbbVie Q1 2026 10-Q]· primary
Reinvestment rate21.0%low
How derived: Because AbbVie's own capital spending is small relative to a $64.4B revenue base and this case assumes strong organic growth from already-owned assets (Skyrizi, Rinvoq, Qulipta, Cerevel and ImmunoGen products now generating revenue), less incremental capital is needed per dollar of new sales, so reinvestment settles at a capital-efficient 21% of after-tax operating profit.
Why this confidence: M&A-driven reinvestment is lumpy and never guided forward ↓, Large intangible amortization distorts the accounting measure of reinvestment ↓, Assumption sits in tension with the very recent $9.93B debt raise ↓, Pharma manufacturing capex is genuinely light and observable in filings ↑
Evidence for
- Prior acquisitions (ImmunoGen, Cerevel) are already contributing to oncology and neuroscience revenue, meaning growth in the forecast window comes from assets already paid for.[AbbVie Q2 2026 Results]· primary
- Management targets returning to roughly 2x net leverage within two to three years of the Apogee close, implying reinvestment moderates after the current deal cycle.[AbbVie prices $9.9B senior notes to fund acquisition]· secondary
Evidence against
- AbbVie just raised roughly $9.93 billion of debt to fund a single acquisition, evidence that its growth model remains capital-hungry rather than capital-light.[AbbVie Form 424B5]· primary
- AbbVie added about $8 billion of net new debt for the Apogee deal, increasing leverage before revenue arrives.[AbbVie Piles on $8 Billion in Debt for Its Apogee Deal]· secondary
Terminal growth2.8%medium
How derived: With the 10-year Treasury near 4.7% setting the ceiling, this case uses 2.8% perpetual growth — roughly long-run US nominal GDP — reasoning that an aging population, expanding immunology and neuroscience indications, and a continually renewed pipeline let AbbVie grow with the broader economy indefinitely rather than decaying like a single-product franchise.
Why this confidence: Constrained below an observable, cited risk-free rate ↑, Supported by eleven years of actual AbbVie revenue history ↑, Assumes no net drag from future patent cliffs in perpetuity ↓
Evidence for
- AbbVie's revenue has compounded from $22.9 billion in 2015 to a guided ~$67.6 billion in 2026 despite absorbing the largest patent cliff in industry history, evidence of a self-renewing franchise.[AbbVie Q2 2026 Results]· primary
- The ~4.7% 10-year Treasury yield leaves ample headroom above a 2.8% perpetual growth assumption, keeping the model internally consistent.[Federal Reserve H.15 Selected Interest Rates]· primary
Evidence against
- AbbVie's revenue actually declined 6.4% in 2023, and Humira fell another 35.9% in Q2 2026, showing patent expiries impose periodic resets that argue against economy-matching perpetual growth.[AbbVie Q2 2026 Results]· primary
Valuation robustness
reliability of the estimate, not a stock rating53 / 100 · Moderate
Formula v1.0.0. Higher means a more reliable estimate — not a recommendation.
Quality checks
Automated model-risk flags — warnings, not recommendations.
- 80% of the intrinsic value rests on the terminal value — a small change to terminal growth moves the valuation a lot.→ terminal growth
- The reinvestment assumption is low-confidence.→ reinvestment
Per-share economics
Business growth after changes in the diluted share count.
| Period | Revenue growth | FCF/share | FCF/share growth | Shares | Share growth |
|---|---|---|---|---|---|
| Q3 2024 | 3.8% | 2.93 | -29.4% | 1.77B | 0.1% |
| Q1 2025 | 8.4% | 0.79 | -63.6% | 1.77B | -0.1% |
| Q2 2025 | 6.6% | 2.76 | 140.6% | 1.77B | 0.0% |
| Q3 2025 | 9.1% | 3.75 | 27.8% | 1.77B | 0.0% |
| Q1 2026 | 12.4% | 2.01 | 154.3% | 1.77B | 0.1% |
| Q2 2026 | 10.2% | 1.76 | -36.2% | 1.77B | 0.0% |
Valuation history every run
History builds as the valuation is recalculated — this is the first recorded run.
Market inputs researched
The 10-year Treasury constant maturity yield reached about 4.70% on August 14, 2026, near a 19-month high of 4.75%, and this long-duration government rate is the standard risk-free benchmark for a US-dollar DCF.
Published regression betas for ABBV cluster between 0.28 (Yahoo Finance 5-year monthly) and 0.54 (Macroaxis versus the Dow), reflecting the defensive, dividend-heavy character of large-cap pharma; single-stock regression betas at the low end are statistically noisy and would imply a cost of equity below AbbVie's own cost of debt, so I take the top of the observed range at 0.55.
Damodaran's implied equity risk premium backed out of S&P 500 prices and expected cash flows stood at 4.23% over the US Treasury bond rate at the start of 2026, and a forward-looking implied ERP is preferable to a historical average because it reflects prices actually prevailing today.
ABBV was quoted at $250.08 in mid-August 2026, corroborated by a reported market capitalization of about $440.8 billion against the 1.771 billion diluted shares in the filings (implying roughly $249 per share), and sits below the July 29, 2026 all-time closing high of $263.30.
AbbVie priced roughly $9.93 billion of senior notes on August 5, 2026 with fixed coupons ranging from 4.500% on the 2028 tranche to 6.100% on the 2066 tranche at issue prices near par, so a 10-year-equivalent blended pre-tax marginal borrowing cost of about 5.3% is the directly observed cost of debt for this issuer at its targeted A2/A- rating.
Generated 8/16/2026, 4:07:47 AM · pipeline v1.1.0